Crescent Biopharma's total assets for Q3 2025 were $138.27M, a decrease of -12.17% from the previous quarter. CBIO total liabilities were $21.63M for the fiscal quarter, a 18.97% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.